Edgestream Partners L.P. Has $2.35 Million Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Edgestream Partners L.P. raised its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 165.3% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,842 shares of the pharmaceutical company's stock after buying an additional 3,640 shares during the quarter. Edgestream Partners L.P.'s holdings in Vertex Pharmaceuticals were worth $2,353,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of VRTX. Edgewood Management LLC raised its stake in Vertex Pharmaceuticals by 7,876.3% during the third quarter. Edgewood Management LLC now owns 1,546,370 shares of the pharmaceutical company's stock valued at $719,186,000 after buying an additional 1,526,983 shares in the last quarter. WCM Investment Management LLC acquired a new stake in Vertex Pharmaceuticals during the fourth quarter valued at approximately $435,899,000. Jennison Associates LLC raised its stake in Vertex Pharmaceuticals by 18.1% during the third quarter. Jennison Associates LLC now owns 5,550,386 shares of the pharmaceutical company's stock valued at $2,581,373,000 after buying an additional 851,054 shares in the last quarter. Wellington Management Group LLP raised its stake in Vertex Pharmaceuticals by 17.2% during the third quarter. Wellington Management Group LLP now owns 4,798,870 shares of the pharmaceutical company's stock valued at $2,231,858,000 after buying an additional 704,421 shares in the last quarter. Finally, Assenagon Asset Management S.A. raised its stake in Vertex Pharmaceuticals by 169.4% during the fourth quarter. Assenagon Asset Management S.A. now owns 839,672 shares of the pharmaceutical company's stock valued at $338,136,000 after buying an additional 528,029 shares in the last quarter. Institutional investors and hedge funds own 90.96% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several research firms have recently commented on VRTX. Citigroup began coverage on Vertex Pharmaceuticals in a report on Thursday, November 14th. They set a "buy" rating and a $575.00 target price for the company. Jefferies Financial Group raised Vertex Pharmaceuticals from a "hold" rating to a "buy" rating and upped their target price for the company from $500.00 to $550.00 in a report on Monday, December 9th. Piper Sandler lowered their target price on Vertex Pharmaceuticals from $535.00 to $533.00 and set an "overweight" rating for the company in a report on Monday, January 27th. JPMorgan Chase & Co. lowered their target price on Vertex Pharmaceuticals from $503.00 to $500.00 and set an "overweight" rating for the company in a report on Monday, December 23rd. Finally, Oppenheimer lowered Vertex Pharmaceuticals from an "outperform" rating to a "market perform" rating in a report on Thursday, December 19th. Ten equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $506.70.

Vertex Pharmaceuticals Price Performance

NASDAQ VRTX traded up $6.02 during trading on Wednesday, reaching $494.36. 121,867 shares of the company traded hands, compared to its average volume of 1,459,369. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69. The stock's 50 day moving average price is $451.99 and its two-hundred day moving average price is $461.34. The company has a market cap of $126.95 billion, a price-to-earnings ratio of -224.12, a P/E/G ratio of 2.11 and a beta of 0.41. Vertex Pharmaceuticals Incorporated has a 1-year low of $377.85 and a 1-year high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its quarterly earnings data on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share for the quarter, missing analysts' consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. As a group, analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Insider Transactions at Vertex Pharmaceuticals

In other news, EVP Ourania Tatsis sold 244 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $455.06, for a total value of $111,034.64. Following the transaction, the executive vice president now directly owns 67,695 shares of the company's stock, valued at $30,805,286.70. The trade was a 0.36 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 1,084 shares of company stock valued at $505,512 in the last three months. 0.20% of the stock is owned by corporate insiders.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.